請用此 Handle URI 來引用此文件:
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/7821
完整後設資料紀錄
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.advisor | 林水龍(Shuei-Liong Lin) | |
dc.contributor.author | Chi-Chun Lin | en |
dc.contributor.author | 林紀均 | zh_TW |
dc.date.accessioned | 2021-05-19T17:54:49Z | - |
dc.date.available | 2022-02-24 | |
dc.date.available | 2021-05-19T17:54:49Z | - |
dc.date.copyright | 2017-02-24 | |
dc.date.issued | 2017 | |
dc.date.submitted | 2017-01-20 | |
dc.identifier.citation | 1. Mutsaers, S.E., et al., Pathogenesis of pleural fibrosis. Respirology, 2004. 9(4): p. 428-40.
2. Kipps, E., D.S. Tan, and S.B. Kaye, Meeting the challenge of ascites in ovarian cancer: new avenues for therapy and research. Nat Rev Cancer, 2013. 13(4): p. 273-82. 3. Mutsaers, S.E., Mesothelial cells: their structure, function and role in serosal repair. Respirology, 2002. 7(3): p. 171-91. 4. Fukata, H., Electron mocroscopic study on normal rat peritoneal mesothelium and its change in absorption of perticulate iron dextran complex. Acta Pathol Jpn, 1963. 13: p. 309-25. 5. Davies, S.J., Peritoneal solute transport and inflammation. Am J Kidney Dis, 2014. 64(6): p. 978-86. 6. Yao, V., et al., Peritoneal mesothelial cells produce cytokines in a murine model of peritonitis. Surg Infect (Larchmt), 2004. 5(3): p. 229-36. 7. Matte, I., et al., Mesothelial cells interact with tumor cells for the formation of ovarian cancer multicellular spheroids in peritoneal effusions. Clin Exp Metastasis, 2016. 8. Miao, Z.F., et al., Tumor-associated mesothelial cells are negative prognostic factors in gastric cancer and promote peritoneal dissemination of adherent gastric cancer cells by chemotaxis. Tumour Biol, 2014. 35(6): p. 6105-11. 9. Devuyst, O., P.J. Margetts, and N. Topley, The pathophysiology of the peritoneal membrane. J Am Soc Nephrol, 2010. 21(7): p. 1077-85. 10. Chen, Y.T., et al., Lineage tracing reveals distinctive fates for mesothelial cells and submesothelial fibroblasts during peritoneal injury. J Am Soc Nephrol, 2014. 25(12): p. 2847-58. 11. Grassmann, A., et al., ESRD patients in 2004: global overview of patient numbers, treatment modalities and associated trends. Nephrol Dial Transplant, 2005. 20(12): p. 2587-93. 12. Czyzewski, L., et al., Assessment of health-related quality of life of patients after kidney transplantation in comparison with hemodialysis and peritoneal dialysis. Ann Transplant, 2014. 19: p. 576-85. 13. Liu, Y., et al., Transition of mesothelial cell to fibroblast in peritoneal dialysis: EMT, stem cell or bystander? Perit Dial Int, 2015. 35(1): p. 14-25. 14. Shiao, C.C., et al., Seven-year follow-up of peritoneal dialysis patients in Taiwan. Perit Dial Int, 2009. 29(4): p. 450-7. 15. Margetts, P.J. and K.S. Brimble, Peritoneal dialysis, membranes and beyond. Curr Opin Nephrol Hypertens, 2006. 15(6): p. 571-6. 16. Fielding, C.A., et al., Interleukin-6 signaling drives fibrosis in unresolved inflammation. Immunity, 2014. 40(1): p. 40-50. 17. Krediet, R.T. and D.G. Struijk, Peritoneal changes in patients on long-term peritoneal dialysis. Nat Rev Nephrol, 2013. 9(7): p. 419-29. 18. Aroeira, L.S., et al., Epithelial to mesenchymal transition and peritoneal membrane failure in peritoneal dialysis patients: pathologic significance and potential therapeutic interventions. J Am Soc Nephrol, 2007. 18(7): p. 2004-13. 19. Habib, S.M., et al., Management of encapsulating peritoneal sclerosis: a guideline on optimal and uniform treatment. Neth J Med, 2011. 69(11): p. 500-7. 20. Schilte, M.N., et al., Factors contributing to peritoneal tissue remodeling in peritoneal dialysis. Perit Dial Int, 2009. 29(6): p. 605-17. 21. Honda, K., et al., Impact of uremia, diabetes, and peritoneal dialysis itself on the pathogenesis of peritoneal sclerosis: a quantitative study of peritoneal membrane morphology. Clin J Am Soc Nephrol, 2008. 3(3): p. 720-8. 22. Padwal, M. and P.J. Margetts, Experimental systems to study the origin of the myofibroblast in peritoneal fibrosis. Kidney Res Clin Pract, 2016. 35(3): p. 133-41. 23. Yung, S. and T.M. Chan, Intrinsic cells: mesothelial cells -- central players in regulating inflammation and resolution. Perit Dial Int, 2009. 29 Suppl 2: p. S21-7. 24. Yamaguchi, N., et al., Newly Developed Neutralized pH Icodextrin Dialysis Fluid: Nonclinical Evaluation. Artif Organs, 2016. 40(8): p. E158-66. 25. Honda, K., et al., Accumulation of advanced glycation end products in the peritoneal vasculature of continuous ambulatory peritoneal dialysis patients with low ultra-filtration. Nephrol Dial Transplant, 1999. 14(6): p. 1541-9. 26. Combet, S., et al., Vascular proliferation and enhanced expression of endothelial nitric oxide synthase in human peritoneum exposed to long-term peritoneal dialysis. J Am Soc Nephrol, 2000. 11(4): p. 717-28. 27. Augustine, T., et al., Encapsulating peritoneal sclerosis: clinical significance and implications. Nephron Clin Pract, 2009. 111(2): p. c149-54; discussion c154. 28. Moinuddin, Z., et al., Encapsulating peritoneal sclerosis-a rare but devastating peritoneal disease. Front Physiol, 2014. 5: p. 470. 29. Park, S.H., Y.L. Kim, and B. Lindholm, Experimental encapsulating peritoneal sclerosis models: pathogenesis and treatment. Perit Dial Int, 2008. 28 Suppl 5: p. S21-8. 30. Mori, Y., et al., A case of a dialysis patient with sclerosing peritonitis successfully treated with corticosteroid therapy alone. Am J Kidney Dis, 1997. 30(2): p. 275-8. 31. Strippoli, R., et al., Molecular Mechanisms Underlying Peritoneal EMT and Fibrosis. Stem Cells Int, 2016. 2016: p. 3543678. 32. Holmdahl, L., et al., Overproduction of transforming growth factor-beta1 (TGF-beta1) is associated with adhesion formation and peritoneal fibrinolytic impairment. Surgery, 2001. 129(5): p. 626-32. 33. Tomura, S., et al., Fibrinogen, coagulation factor VII, tissue plasminogen activator, plasminogen activator inhibitor-1, and lipid as cardiovascular risk factors in chronic hemodialysis and continuous ambulatory peritoneal dialysis patients. Am J Kidney Dis, 1996. 27(6): p. 848-54. 34. Savagner, P., Leaving the neighborhood: molecular mechanisms involved during epithelial-mesenchymal transition. Bioessays, 2001. 23(10): p. 912-23. 35. Piek, E., et al., TGF-(beta) type I receptor/ALK-5 and Smad proteins mediate epithelial to mesenchymal transdifferentiation in NMuMG breast epithelial cells. J Cell Sci, 1999. 112 ( Pt 24): p. 4557-68. 36. Fan, J.M., et al., Transforming growth factor-beta regulates tubular epithelial-myofibroblast transdifferentiation in vitro. Kidney Int, 1999. 56(4): p. 1455-67. 37. Iwano, M., et al., Evidence that fibroblasts derive from epithelium during tissue fibrosis. J Clin Invest, 2002. 110(3): p. 341-50. 38. Yang, A.H., J.Y. Chen, and J.K. Lin, Myofibroblastic conversion of mesothelial cells. Kidney Int, 2003. 63(4): p. 1530-9. 39. Yanez-Mo, M., et al., Peritoneal dialysis and epithelial-to-mesenchymal transition of mesothelial cells. N Engl J Med, 2003. 348(5): p. 403-13. 40. Margetts, P.J., et al., Transient overexpression of TGF-{beta}1 induces epithelial mesenchymal transition in the rodent peritoneum. J Am Soc Nephrol, 2005. 16(2): p. 425-36. 41. Aguilera, A., et al., Epithelial to mesenchymal transition as a triggering factor of peritoneal membrane fibrosis and angiogenesis in peritoneal dialysis patients. Curr Opin Investig Drugs, 2005. 6(3): p. 262-8. 42. Hung, K.Y., et al., Pentoxifylline modulates intracellular signalling of TGF-beta in cultured human peritoneal mesothelial cells: implications for prevention of encapsulating peritoneal sclerosis. Nephrol Dial Transplant, 2003. 18(4): p. 670-6. 43. Mortier, S., A.S. De Vriese, and N. Lameire, Recent concepts in the molecular biology of the peritoneal membrane - implications for more biocompatible dialysis solutions. Blood Purif, 2003. 21(1): p. 14-23. 44. Mortier, S., et al., Effects of conventional and new peritoneal dialysis fluids on leukocyte recruitment in the rat peritoneal membrane. J Am Soc Nephrol, 2003. 14(5): p. 1296-306. 45. Devuyst, O., N. Topley, and J.D. Williams, Morphological and functional changes in the dialysed peritoneal cavity: impact of more biocompatible solutions. Nephrol Dial Transplant, 2002. 17 Suppl 3: p. 12-5. 46. Davies, S.J., et al., Determinants of peritoneal membrane function over time. Semin Nephrol, 2011. 31(2): p. 172-82. 47. Cho, Y., C.M. Hawley, and D.W. Johnson, Clinical causes of inflammation in peritoneal dialysis patients. Int J Nephrol, 2014. 2014: p. 909373. 48. Lambie, M., et al., Independent effects of systemic and peritoneal inflammation on peritoneal dialysis survival. J Am Soc Nephrol, 2013. 24(12): p. 2071-80. 49. Lambie, M.R., et al., Peritoneal inflammation precedes encapsulating peritoneal sclerosis: results from the GLOBAL Fluid Study. Nephrol Dial Transplant, 2016. 31(3): p. 480-6. 50. Gerber, S.A., et al., Preferential attachment of peritoneal tumor metastases to omental immune aggregates and possible role of a unique vascular microenvironment in metastatic survival and growth. Am J Pathol, 2006. 169(5): p. 1739-52. 51. Hurst, S.M., et al., Il-6 and its soluble receptor orchestrate a temporal switch in the pattern of leukocyte recruitment seen during acute inflammation. Immunity, 2001. 14(6): p. 705-14. 52. Masunaga, Y., et al., Ascites from patients with encapsulating peritoneal sclerosis augments NIH/3T3 fibroblast proliferation. Ther Apher Dial, 2003. 7(5): p. 486-93. 53. McLoughlin, R.M., et al., Interplay between IFN-gamma and IL-6 signaling governs neutrophil trafficking and apoptosis during acute inflammation. J Clin Invest, 2003. 112(4): p. 598-607. 54. Mozaffarian, A., et al., Mechanisms of oncostatin M-induced pulmonary inflammation and fibrosis. J Immunol, 2008. 181(10): p. 7243-53. 55. Margetts, P.J., et al., Inflammatory cytokines, angiogenesis, and fibrosis in the rat peritoneum. Am J Pathol, 2002. 160(6): p. 2285-94. 56. Tekstra, J., et al., Identification of the major chemokines that regulate cell influxes in peritoneal dialysis patients. J Am Soc Nephrol, 1996. 7(11): p. 2379-84. 57. Haslinger, B., et al., Hyaluronan fragments induce the synthesis of MCP-1 and IL-8 in cultured human peritoneal mesothelial cells. Cell Tissue Res, 2001. 305(1): p. 79-86. 58. Breborowicz, A., et al., Synthesis of hyaluronic acid by human peritoneal mesothelial cells: effect of cytokines and dialysate. Perit Dial Int, 1996. 16(4): p. 374-8. 59. Ha, H., et al., Effects of conventional and new peritoneal dialysis solutions on human peritoneal mesothelial cell viability and proliferation. Perit Dial Int, 2000. 20 Suppl 5: p. S10-8. 60. Margetts, P.J., et al., Gene transfer of transforming growth factor-beta1 to the rat peritoneum: effects on membrane function. J Am Soc Nephrol, 2001. 12(10): p. 2029-39. 61. Kawai, T. and S. Akira, The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol, 2010. 11(5): p. 373-84. 62. Colmont, C.S., et al., Human peritoneal mesothelial cells respond to bacterial ligands through a specific subset of Toll-like receptors. Nephrol Dial Transplant, 2011. 26(12): p. 4079-90. 63. Kawasaki, T. and T. Kawai, Toll-like receptor signaling pathways. Front Immunol, 2014. 5: p. 461. 64. Raby, A.C., et al., Toll-Like Receptors 2 and 4 Are Potential Therapeutic Targets in Peritoneal Dialysis-Associated Fibrosis. J Am Soc Nephrol, 2016. 65. Wang, H.H. and C.Y. Lin, Interleukin-12 and -18 levels in peritoneal dialysate effluent correlate with the outcome of peritonitis in patients undergoing peritoneal dialysis: implications for the Type I/Type II T-cell immune response. Am J Kidney Dis, 2005. 46(2): p. 328-38. 66. Wang, H.H., T.Y. Lee, and C.Y. Lin, Kinetics and involvement of interleukin-17 in the outcome of peritonitis in nondiabetic patients undergoing peritoneal dialysis. J Chin Med Assoc, 2011. 74(1): p. 11-5. 67. Mi, S., et al., Blocking IL-17A promotes the resolution of pulmonary inflammation and fibrosis via TGF-beta1-dependent and -independent mechanisms. J Immunol, 2011. 187(6): p. 3003-14. 68. Rodrigues-Diez, R., et al., IL-17A is a novel player in dialysis-induced peritoneal damage. Kidney Int, 2014. 86(2): p. 303-15. 69. Clark, R.B., et al., The nuclear receptor PPAR gamma and immunoregulation: PPAR gamma mediates inhibition of helper T cell responses. J Immunol, 2000. 164(3): p. 1364-71. 70. Sandoval, P., et al., PPAR-gamma agonist rosiglitazone protects peritoneal membrane from dialysis fluid-induced damage. Lab Invest, 2010. 90(10): p. 1517-32. 71. Zweers, M.M., et al., Ultrastructure of basement membranes of peritoneal capillaries in a chronic peritoneal infusion model in the rat. Nephrol Dial Transplant, 2001. 16(3): p. 651-4. 72. Beelen, R.H., et al., Rat models in peritoneal dialysis. Nephrol Dial Transplant, 2001. 16(3): p. 672-4. 73. Gonzalez-Mateo, G.T., et al., Chronic exposure of mouse peritoneum to peritoneal dialysis fluid: structural and functional alterations of the peritoneal membrane. Perit Dial Int, 2009. 29(2): p. 227-30. 74. Wang, J., et al., The role of peritoneal alternatively activated macrophages in the process of peritoneal fibrosis related to peritoneal dialysis. Int J Mol Sci, 2013. 14(5): p. 10369-82. 75. Zareie, M., et al., Peritoneal dialysis fluid-induced changes of the peritoneal membrane are reversible after peritoneal rest in rats. Nephrol Dial Transplant, 2005. 20(1): p. 189-93. 76. Kato, H., et al., Atrial natriuretic peptide ameliorates peritoneal fibrosis in rat peritonitis model. Nephrol Dial Transplant, 2012. 27(2): p. 526-36. 77. Biswas, S.K. and A. Mantovani, Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nat Immunol, 2010. 11(10): p. 889-96. 78. van Furth, R., et al., The mononuclear phagocyte system: a new classification of macrophages, monocytes, and their precursor cells. Bull World Health Organ, 1972. 46(6): p. 845-52. 79. Ginhoux, F., et al., Fate mapping analysis reveals that adult microglia derive from primitive macrophages. Science, 2010. 330(6005): p. 841-5. 80. Schulz, C., et al., A lineage of myeloid cells independent of Myb and hematopoietic stem cells. Science, 2012. 336(6077): p. 86-90. 81. Bain, C.C., et al., Resident and pro-inflammatory macrophages in the colon represent alternative context-dependent fates of the same Ly6Chi monocyte precursors. Mucosal Immunol, 2013. 6(3): p. 498-510. 82. Tamoutounour, S., et al., Origins and functional specialization of macrophages and of conventional and monocyte-derived dendritic cells in mouse skin. Immunity, 2013. 39(5): p. 925-38. 83. Gentek, R., K. Molawi, and M.H. Sieweke, Tissue macrophage identity and self-renewal. Immunol Rev, 2014. 262(1): p. 56-73. 84. Lin, S.L., et al., Macrophage Wnt7b is critical for kidney repair and regeneration. Proc Natl Acad Sci U S A, 2010. 107(9): p. 4194-9. 85. Wynn, T.A., A. Chawla, and J.W. Pollard, Macrophage biology in development, homeostasis and disease. Nature, 2013. 496(7446): p. 445-55. 86. Lin, S.L., et al., Bone marrow Ly6Chigh monocytes are selectively recruited to injured kidney and differentiate into functionally distinct populations. J Immunol, 2009. 183(10): p. 6733-43. 87. Braga, T.T., J.S. Agudelo, and N.O. Camara, Macrophages During the Fibrotic Process: M2 as Friend and Foe. Front Immunol, 2015. 6: p. 602. 88. Sica, A. and A. Mantovani, Macrophage plasticity and polarization: in vivo veritas. J Clin Invest, 2012. 122(3): p. 787-95. 89. Ghosn, E.E., et al., Two physically, functionally, and developmentally distinct peritoneal macrophage subsets. Proc Natl Acad Sci U S A, 2010. 107(6): p. 2568-73. 90. Davies, L.C., et al., Tissue-resident macrophages. Nat Immunol, 2013. 14(10): p. 986-95. 91. Okabe, Y. and R. Medzhitov, Tissue-specific signals control reversible program of localization and functional polarization of macrophages. Cell, 2014. 157(4): p. 832-44. 92. Gautier, E.L., et al., Gata6 regulates aspartoacylase expression in resident peritoneal macrophages and controls their survival. J Exp Med, 2014. 211(8): p. 1525-31. 93. Accarias, S., et al., Single-cell analysis reveals new subset markers of murine peritoneal macrophages and highlights macrophage dynamics upon Staphylococcus aureus peritonitis. Innate Immun, 2016. 22(5): p. 382-92. 94. Wynn, T.A. and L. Barron, Macrophages: master regulators of inflammation and fibrosis. Semin Liver Dis, 2010. 30(3): p. 245-57. 95. Duffield, J.S., et al., Selective depletion of macrophages reveals distinct, opposing roles during liver injury and repair. J Clin Invest, 2005. 115(1): p. 56-65. 96. Wynn, T.A. and T.R. Ramalingam, Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat Med, 2012. 18(7): p. 1028-40. 97. Mosser, D.M. and J.P. Edwards, Exploring the full spectrum of macrophage activation. Nat Rev Immunol, 2008. 8(12): p. 958-69. 98. Murray, P.J. and T.A. Wynn, Protective and pathogenic functions of macrophage subsets. Nat Rev Immunol, 2011. 11(11): p. 723-37. 99. Greenfield, L., et al., Nucleotide sequence of the structural gene for diphtheria toxin carried by corynebacteriophage beta. Proc Natl Acad Sci U S A, 1983. 80(22): p. 6853-7. 100. Honjo, T., Y. Nishizuka, and O. Hayaishi, Diphtheria toxin-dependent adenosine diphosphate ribosylation of aminoacyl transferase II and inhibition of protein synthesis. J Biol Chem, 1968. 243(12): p. 3553-5. 101. Naglich, J.G., et al., Expression cloning of a diphtheria toxin receptor: identity with a heparin-binding EGF-like growth factor precursor. Cell, 1992. 69(6): p. 1051-61. 102. Saito, M., et al., Diphtheria toxin receptor-mediated conditional and targeted cell ablation in transgenic mice. Nat Biotechnol, 2001. 19(8): p. 746-50. 103. Buch, T., et al., A Cre-inducible diphtheria toxin receptor mediates cell lineage ablation after toxin administration. Nat Methods, 2005. 2(6): p. 419-26. 104. Lin, S.L., et al., Pericytes and perivascular fibroblasts are the primary source of collagen-producing cells in obstructive fibrosis of the kidney. Am J Pathol, 2008. 173(6): p. 1617-27. 105. Peters, S.O., et al., Quantitative polymerase chain reaction-based assay with fluorogenic Y-chromosome specific probes to measure bone marrow chimerism in mice. J Immunol Methods, 2002. 260(1-2): p. 109-16. 106. Qian, B.Z., et al., CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature, 2011. 475(7355): p. 222-5. 107. Hashimoto, D., et al., Tissue-resident macrophages self-maintain locally throughout adult life with minimal contribution from circulating monocytes. Immunity, 2013. 38(4): p. 792-804. 108. Wang, S., et al., TGF-beta/Smad3 signalling regulates the transition of bone marrow-derived macrophages into myofibroblasts during tissue fibrosis. Oncotarget, 2016. 7(8): p. 8809-22. 109. Meng, X.M., et al., Inflammatory macrophages can transdifferentiate into myofibroblasts during renal fibrosis. Cell Death Dis, 2016. 7(12): p. e2495. 110. Theiss, A.L., et al., Tumor necrosis factor (TNF) alpha increases collagen accumulation and proliferation in intestinal myofibroblasts via TNF receptor 2. J Biol Chem, 2005. 280(43): p. 36099-109. 111. Porter, K.E., et al., Tumor necrosis factor alpha induces human atrial myofibroblast proliferation, invasion and MMP-9 secretion: inhibition by simvastatin. Cardiovasc Res, 2004. 64(3): p. 507-15. 112. Loschko, J., et al., Inducible targeting of cDCs and their subsets in vivo. J Immunol Methods, 2016. 434: p. 32-8. 113. Hume, D.A. and K.P. MacDonald, Therapeutic applications of macrophage colony-stimulating factor-1 (CSF-1) and antagonists of CSF-1 receptor (CSF-1R) signaling. Blood, 2012. 119(8): p. 1810-20. 114. MacDonald, K.P., et al., An antibody against the colony-stimulating factor 1 receptor depletes the resident subset of monocytes and tissue- and tumor-associated macrophages but does not inhibit inflammation. Blood, 2010. 116(19): p. 3955-63. 115. Geissmann, F., et al., Blood monocytes: distinct subsets, how they relate to dendritic cells, and their possible roles in the regulation of T-cell responses. Immunol Cell Biol, 2008. 86(5): p. 398-408. 116. Wei, S., et al., Modulation of CSF-1-regulated post-natal development with anti-CSF-1 antibody. Immunobiology, 2005. 210(2-4): p. 109-19. 117. Cenci, S., et al., M-CSF neutralization and egr-1 deficiency prevent ovariectomy-induced bone loss. J Clin Invest, 2000. 105(9): p. 1279-87. 118. Radi, Z.A., et al., Increased serum enzyme levels associated with kupffer cell reduction with no signs of hepatic or skeletal muscle injury. Am J Pathol, 2011. 179(1): p. 240-7. | |
dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/7821 | - |
dc.description.abstract | 末期腎病的起因大多來自於糖尿性腎病變、腎絲球腎炎和高血壓性腎病變所引起。末期腎病的病人需要進行透析或腎臟移植等治療以取代其喪失的腎臟功能並維持健康,腹膜透析是其中的一個選擇。比起血液透析,腹膜透析有許多優點,包含早期存活率較高、可自行在家操作、費用較低…等,因此吸引許多病人選擇這種治療。然而長時間的腹膜透析仍會造成許多問題的產生,其中最嚴重的問題為腹膜纖維化的形成,使得病人沒辦法繼續進行透析而必須採取其他治療方法。因此,預防及減緩腹膜纖維化成為臨床上必須解決的問題。在我們先前的研究中發現,在腹膜纖維化的過程中,間皮下纖維母細胞 (submesothelail fibroblast) 是肌纖維母細胞的主要來源,並非來自骨髓的纖維細胞或間皮細胞。然而在這過程中巨噬細胞所扮演的角色仍尚未被釐清,因此我們想探討不同來源的巨噬細胞在腹膜纖維化的過程中分別扮演什麼角色。
我們利用Csf1r-Cre/Esr1Tg;Rs26fstdTomato/+ 小鼠,其巨噬細胞給予Tamoxifen的誘導下可產生紅色螢光,可藉此觀察當腹膜纖維化時,巨噬細胞的數量及位置。在我們的實驗結果中發現,當給予次氯酸鈉的刺激之後,巨噬細胞的數量會顯著的增加並且累積在腹膜中。因為巨噬細胞顯著增加在受傷的腹膜上,我再利用基因技術讓小鼠巨噬細胞可以因為注射白喉毒素而將巨噬細胞去除,發現將巨噬細胞去除時,原本因纖維化而增厚的腹膜厚度不僅減少,連肌纖維母細胞的數量也減少了。此表示巨噬細胞對於間皮下纖維母細胞轉變為肌纖維母細胞的過程有特定的作用。除此之外,我們也發現這些巨噬細胞並不會表現肌纖維母細胞特定因子(α-smooth muscle actin ; α-SMA)及膠原蛋白 (collagen),這個結果顯示巨噬細胞在我們的實驗模式中並不會轉變為肌纖維母細胞。為了探討來自循環及組織駐留的巨噬細胞,我們利用連體共生(parabiosis)將CAG-EGFPTg 和 C57BL/6 小鼠縫合,經過四週後會產生微循環,彼此的周邊血液可進行交換,但腹腔中的細胞並不受影響。實驗結果顯示在次氯酸鈉刺激後,在腹腔內會有約40%的巨噬細胞來自於循環中,而剩下60%則是組織中的巨噬細胞經由刺激之後增生而來。利用連體共生與基因技術去除來自循環或組織駐留的巨噬細胞,並無法釐清究竟來自循環或組織駐留的巨噬細胞對於腹膜纖維化的影響何者較為重要。 總結來說,當腹膜纖維化時,巨噬細胞會堆積在受傷的腹膜中,但不會轉變成為肌纖維母細胞,因此其扮演的角色可能是藉由細胞間的交互作用影響間皮下纖維母細胞轉變為肌纖維母細胞。循環中及組織中的巨噬細胞在腹膜纖維化過程中,其數量的平衡及表型的變化需要進一步研究。 | zh_TW |
dc.description.abstract | Diabetic kidney disease, glomerulonephritis, and hypertensive nephropathy are the leading causes of end-stage renal disease (ESRD). Peritoneal dialysis (PD) is one of therapies for ESRD. PD holds many therapeutic advantages including early survival benefit, the convenience of home therapy, and lower healthcare costs, which are particularly attractive to patients. However, patients will face some challenges especially peritoneal fibrosis after long-term dialysis. Prevention and attenuation of peritoneal fibrosis is an unmet medical need for patients with peritoneal dialysis. In our previous study, we proved that submesothelial fibroblasts are the major origin of myofibroblasts in peritoneal fibrosis. However, the roles of monocytes/macrophages during peritoneal fibrosis are not clear. We tried to figure out the roles of circulating monocyte- derived macrophages and tissue resident macrophages during peritoneal fibrosis in this study.
We used Csf1r-Cre/Esr1Tg;Rs26fstdTomato/+ mice whose Csf1r-expressing cells including bone-marrow-derived macrophages and yolk sac macrophages expressed red fluorescence protein after tamoxifen-induced genetic recombination. Besides, parabiotic model made by two mice were used to create chimeric mice for study of circulating monocyte-derived macrophages. Sodium hypochlorite was used to induce peritoneal fibrosis. We first analyzed tissue-resident macrophages in peritoneal cavity and grouped them into two subsets, large peritoneal macrophage (LPM) and small peritoneal macrophage (SPM), as previous studies. After hypochlorite injury, we observed many macrophages accumulated in peritoneum. Selective macrophage ablation in Csf1r-Cre/Esr1Tg;Rs26fstdTomato/+;Rs26iDTR/+ mice was performed by administration of diphtheria toxin during peritoneal fibrosis. The thickness of injured peritoneum and the number of myofibroblasts were decreased markedly under macrophage depletion. Immunofluorescence staining showed that macrophages did not express collagen and a-SMA markers, suggesting macrophages did not transit into myofibroblasts during peritoneal fibrosis. In parabiotic model made between CAG-EGFPTg and wild type C57BL/6 mice, we demonstrated that about 40% of peritoneal macrophages were derived from circulating monocytes and the rest came from tissue-resident macrophages during peritoneal fibrosis. Selective ablation by diphtheria toxin in the parabiotic model made from Csf1r-Cre/Esr1Tg;Rs26iDTR/+ and Rs26iDTR/+ littermate could not clearly clarify the contribution of circulating monocytes-derived and resident macrophages to peritoneal fibrosis. In conclusion, our study implicated that macrophages have decisive effects on peritoneal fibrosis but not through macrophage-myofibroblast transition (MMT) pathway. Cross-talk between peritoneal macrophages and submesothelial fibroblasts should be one the underlying mechanisms for the differentiation and scar formation of peritoneal myofibroblasts after injury. The importance of circulating monocyte-derived macrophages and tissue-resident macrophages balance needs further study. | en |
dc.description.provenance | Made available in DSpace on 2021-05-19T17:54:49Z (GMT). No. of bitstreams: 1 ntu-106-R03441007-1.pdf: 3217234 bytes, checksum: d98cd4015a01a2d155d85a578068eae4 (MD5) Previous issue date: 2017 | en |
dc.description.tableofcontents | 口試委員會審定書 #
中文摘要 i ABSTRACT iii CONTENTS v LIST OF FIGURES viii Abbreviations ix Chapter 1 Introduction 1 1.1 Physiology of peritoneum 1 1.1.1 Mesothelial cells 1 1.2 Peritoneal dialysis 2 1.3 Peritoneal fibrosis 2 1.3.1 Risk factors 3 1.3.2 The mechanism of peritoneal fibrosis 4 1.4 Animal model of peritoneal dialysis and fibrosis 13 1.4.1 Methods for establishing rodent PD models 13 1.4.2 Peritoneal fibrosis models 14 1.5 Macrophage 15 1.5.1 Origin and functions of tissue macrophages 15 1.5.2 Peritoneal macrophage 16 1.5.3 Macrophage in fibrosis 17 1.5.4 Animal model of conditional macrophage ablation 18 1.6 The purpose of my study 19 Chapter 2 Material and Method 20 2.1 Materials 20 2.1.1 Animals 20 2.1.2 Diphtheria toxin (DT) 23 2.1.3 Chemicals 23 2.1.4 Buffers 26 2.1.5 Antibodies 28 2.1.6 Instruments 31 2.2 Methods 32 2.2.1 Peritoneal fibrosis model 32 2.2.2 Chimeric mice model 32 2.2.3 Sample preparation 33 2.2.4 Flow cytometry 33 2.2.5 Fluorescence-activated cell sorting (FACS) system 34 2.2.6 Immunofluorescence stain 34 2.2.7 Masson’s Trichrome stain 35 2.2.8 Isolation of bone marrow cells and measurement of engraftment efficiency 35 2.2.9 Statistical analysis 35 Chapter 3 Results 36 3.1 Identified subsets of macrophages in peritoneal cavity 36 3.2 Macrophage increased in injured peritoneum 36 3.3 Macrophage ablation by diphtheria toxin 37 3.4 Macrophage ablation attenuated peritoneal fibrosis 37 3.5 Macrophages did not produce collagen and a-SMA in injured peritoneum 38 3.6 Chimeric mice were generated by parabiosis 39 3.7 Circulating monocytes-derived macrophages recruited to peritoneal cavity after injury 39 3.8 Macrophage ablation in parabiosis model 40 Chapter 4 Discussion 41 Chapter 5 Conclusion and future prospects 45 REFERENCE 61 | |
dc.language.iso | en | |
dc.title | 巨噬細胞在腹膜纖維化中的角色 | zh_TW |
dc.title | Macrophage in peritoneal fibrosis | en |
dc.type | Thesis | |
dc.date.schoolyear | 105-1 | |
dc.description.degree | 碩士 | |
dc.contributor.oralexamcommittee | 姜文智,吳明修 | |
dc.subject.keyword | 巨噬細胞,肌纖維母細胞,腹膜纖維化,間皮下纖維母細胞,連體共生, | zh_TW |
dc.subject.keyword | macrophage,peritoneum fibrosis,myofibroblast,submesothelial fibroblast,parabiosis, | en |
dc.relation.page | 67 | |
dc.identifier.doi | 10.6342/NTU201700152 | |
dc.rights.note | 同意授權(全球公開) | |
dc.date.accepted | 2017-01-20 | |
dc.contributor.author-college | 醫學院 | zh_TW |
dc.contributor.author-dept | 生理學研究所 | zh_TW |
顯示於系所單位: | 生理學科所 |
文件中的檔案:
檔案 | 大小 | 格式 | |
---|---|---|---|
ntu-106-1.pdf | 3.14 MB | Adobe PDF | 檢視/開啟 |
系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。